Gopi Suvanam, founderof InvestWorks told CNBC-TV18, "Pharma is definitely one sector I am looking at. Ranbaxy Laboratories has a lot of news driven flow. The margins seems to be improving, which is one area I am focusing on. Although it is still negative from profitability standpoint and cash flows have become significantly positive which is good for the investors."
"Pharma is one sector which will continue to perform and given that I have a strong bullish view not only on earnings re-rating but also on performance, I would look at other pharma stocks which might be coming up in results in next couple of days. Cipla is one such stock and I will also look at Lupin," he said.
"This is one sector I am really bullish on. I would avoid rest of the sectors including midcap at the moment. Maybe I would be selective in choosing some midcap IT stocks or maybe heavily undervalued midcap banking stocks but at the moment I would not touch midcap."
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
